Clinical trials: Neoplasm Circulating Cells
Cervical Cancer, Ovarian Clear Cell Carcinoma
Asian Multicenter Prospective Study of ctDNA Sequencing
This study is a genetic analysis of aberrations in circulating tumor DNA (ctDNA) in patients in Asian countries. This study protocol is divided into parts describing several subanalyses that differ in terms of cancer types…
- Conditions
- Cervical Cancer, Ovarian Clear Cell Carcinoma, Nasopharyngeal Carcinoma, Ovarian Cancer
- Trial name
- A-TRAIN (NCT05099978)
- Testing
- NGS analysis of ctDNA
- Where
- 19 sites in Japan, Malaysia and 6 more
- Volunteers
- 506 people
- Sponsor
- National Cancer Center, Japan
Hepatocellular Carcinoma, Circulating Tumor Cell
Prognostic Value of Liver Cancer CTCs Isolated by a Novel Microfluidic Platform
This study aims to isolate CTCs in peripheral venous blood of liver cancer patients by inertial focusing principle-based microfluidic device, determine the relationship between the number of CTCs and patient prognosis and…
- Conditions
- Hepatocellular Carcinoma, Circulating Tumor Cell, Whole Genome Sequencing
- Trial name
- NCT05242237
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
On-treatment Surveillance of Tumor Evolution and Response to Systemic Treatment in Bile Duct and Liver Cancer
The BILLIONSTARS study is a prospective, single arm observational study inviting patients diagnosed with hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCC) who are to be recommended locoregional intervention by surgery…
- Trial name
- BILLIONSTARS (NCT06877637)
- Where
- 3 sites in Sweden
- Volunteers
- 150 people
- Sponsor
- Region Skane
Breast Neoplasms
A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients
The purpose of this study is to determine the effects of Plavix and aspirin in women with metastatic breast cancer.
- Trial name
- NCT00263211
- Testing
- Plavix, Aspirin
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Glioblastoma, Molecular Disease
Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.
Glioblastomas (GBM) are rare tumors of poor prognosis and their treatment is based on surgery followed by radiochemotherapy. Clinical and imaging evaluation is not always straightforward: the more or less complete surgery, the…
- Trial name
- Bi-GLAM (NCT03115138)
- Testing
- Correlation between molecular anomalies of the primary tumor and circulating tumor DNA
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Circulating Tumor Cell, Volatile Organic Chemicals
Diagnostic Power Comparison Between VOCs and CTCs
Early diagnosis of malignant tumors is pivotal for improving their prognoses. Circulating tumor cells (CTC) in peripheral blood and Volatile organic compounds (VOCs) in exhaled breath are newly developed diagnosis method.
- Conditions
- Circulating Tumor Cell, Volatile Organic Chemicals, Breast Cancer, Gastric Cancer
- Trial name
- NCT03958812
- Testing
- Circulating tumor cells, Volatile organic compounds
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Anhui Medical University
Gastric Cancer, Gastro-oesophageal Junction Cancer
Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Gastric Cancer
To explore the clinical value of dynamic detection of circulating tumor cells(CTCs), circulating tumor DNA(ctDNA) and cell-free DNA(cfDNA) in neoadjuvant chemotherapy and operation of resectable or locally advanced gastric or…
- Trial name
- NCT03957564
- Testing
- Neoadjuvant chemotherapy with PSOX regimen., Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in plasma., Detect the tumor related DNA in pathological tissues after operation.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Affiliated Hospital of Qinghai University
Metastatic Breast Cancer
Enumeration and Molecular Characterization of Circulating Tumour Cells in Women With Metastatic Breast Cancer
Women with metastatic breast cancer, receiving first line treatment of any kind (chemotherapy, endocrine treatment or treatment with antibodies) will be included in this trial.
- Trial name
- CTC-MBC (NCT01322893)
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Lund University Hospital
Aggressive B-cell Lymphomas
Proof of Concept for Real-time Multicentric Monitoring of MRD by PET and ctDNA in Aggressive B-Cell Lymphomas
RT4 (REAL TIME TAILORED THERAPY) study was designed as a national, multicenter proof of concept aiming to demonstrate the technical and operational capacity of the French Connect network and the Positron Emission Tomography (PET)…
- Trial name
- RT4 (NCT07514715)
- Testing
- blood test
- Where
- 30 sites in France
- Volunteers
- 129 people
- Sponsor
- The Lymphoma Academic Research Organisation
Melanoma (Skin)
Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma
BRAF V600-mutant metastatic melanoma are commonly treated using a combination of anti-BRAF and anti-MEK tyrosine kinase inhibitors (TKIs).
- Trial name
- OPTIMEL (NCT03416933)
- Testing
- Blood sampling
- Where
- 4 sites in France
- Volunteers
- 35 people
- Sponsor
- Institut de Cancérologie de Lorraine
Clear Cell Renal Cancer, Circulating Tumor Cells
Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal Cancer
Circulating tumor cells (CTCs) have prognostic value in several tumor types, and increasing evidence suggests that molecular characterization of CTCs can serve as a "liquid biopsy" to understand and address treatment resistance.
- Conditions
- Clear Cell Renal Cancer, Circulating Tumor Cells, Circulating Endothelial Cells, Prognostic Biomarkers
- Trial name
- NCT02499458
- Testing
- None- observational study
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Circulating Tumor Cells
Cancer DNA Screening Pilot Study (CANDACE)
The investigators have developed an assay that can sensitively and specifically detect DNA mutations circulating in human plasma that may be indicators of the presence of a solid tumor.
- Trial name
- CANDACE (NCT02808884)
- Testing
- Circulating tumor DNA assay
- Where
- Canada
- Volunteers
- 1,514 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
Cancer, Breast Cancer
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the…
- Conditions
- Cancer, Breast Cancer, Lung Cancer, Colon Cancer
- Trial name
- LIBERATE (NCT03702309)
- Where
- Canada
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Genistein in Treating Patients With Prostate Cancer
RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This randomized phase II trial is studying how well genistein works in treating patients with prostate…
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer
- Trial name
- NCT01126879
- Testing
- genistein, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Non Small Cell Lung Cancer, Complete Surgical Resection
Using ctDNA to Determine Therapies for Lung Cancer
This is a study to look at whether the presence of circulating tumour DNA (ctDNA) in the blood can help to predict whether giving adjuvant treatment after surgery can decrease the chance of the cancer coming back in people with…
- Conditions
- Non Small Cell Lung Cancer, Complete Surgical Resection, Circulating Tumor DNA
- Trial name
- ctDNA Lung RCT (NCT04966663)
- Testing
- Nivolumab, Pemetrexed, Gemcitabine
- Where
- Canada
- Volunteers
- 66 people
- Sponsor
- University Health Network, Toronto
Metastatic Breast Cancer
Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer
The purpose of this study is to evaluate whether increased mutant ESR1 allele fraction in plasma ctDNA 3-6 weeks after initiating salvage endocrine therapy is predictive of progression free survival in patients with ER+…
- Trial name
- NCT03161834
- Testing
- Observational
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lung Cancer, NSCLC
Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
The vast majority of patients with stage I (tumors ≥ 4cm), IIA, IIB (and select stage III) NSCLC are managed with upfront surgery, followed by adjuvant chemotherapy.
- Trial name
- NCT04367311
- Testing
- Atezolizumab, Docetaxel, Cisplatin
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nasser Hanna
Leiomyosarcoma, Pleomorphic Liposarcoma
Detection of Circulating Tumor Cells in Patients With Sarcomas
The sarcomas represent 1% of all cancers in adults, 8% in adolescents and young people, and 10% in children. Even though it is a rare cancer, it contributes to a significant loss of years of life in comparison with other types of…
- Conditions
- Leiomyosarcoma, Pleomorphic Liposarcoma, Synovial Sarcoma, Liposarcoma
- Trial name
- CTCS (NCT02983539)
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- AC Camargo Cancer Center
Non Small Cell Lung Cancer
Enumeration of Circulating Tumour Cells (CTCs) in Patients With Advanced Solid Malignancy Using Complementary Metal Oxide Semiconductor (CMOS) Technology
Modern anti-cancer treatments are focused on development of molecular based therapies i.e. specific treatments targeted against underlying biological processes.
- Trial name
- NCT01596452
- Where
- Singapore
- Volunteers
- 31 people
- Sponsor
- National University Hospital, Singapore
Circulating Tumor Cell, Squamous Cell Carcinoma of the Head and Neck
CTC Detection Rate in SCCHN With a in Vivo Device
Detection rate and isolation yield of CTC is low in squamous cell carcinoma of head and neck (SCCHN) with in vitro approaches rely on limited sample volumes.
- Trial name
- NCT03071900
- Testing
- circulating tumor cell analysis
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Nanjing Tongren Hospital